This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human DcR3/TNFRSF6B Fc Chimera Protein, CF
catalog :
142-DC
quantity :
100 ug
price :
369 USD
citations: 9
Reference
Idelson M, Alper R, Obolensky A, Yachimovich Cohen N, Rachmilewitz J, Ejzenberg A, et al. Immunological Properties of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells. Stem Cell Reports. 2018;11:681-695 pubmed publisher
Clarke A, Poulton L, Shim D, Mabon D, Butt D, Pollard M, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10:664-677 pubmed publisher
Connor J, Felder M, Kapur A, Onujiogu N. DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1. BMC Cancer. 2012;12:176 pubmed publisher
Tso G, Law H, Tu W, Chan G, Lau Y. Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells. Stem Cells. 2010;28:939-54 pubmed publisher
Morishige T, Yoshioka Y, Inakura H, Tanabe A, Yao X, Tsunoda S, et al. Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy. Biomaterials. 2010;31:3357-63 pubmed publisher
Colucci S, Brunetti G, Mori G, Oranger A, Centonze M, Mori C, et al. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia. 2009;23:2139-46 pubmed publisher
Mueller A, Pedre X, Killian S, David M, Steinbrecher A. The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol. 2009;209:57-64 pubmed publisher
Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, et al. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol. 2007;178:192-200 pubmed
Edwards J, Sun S, Locklin R, Shipman C, Adamopoulos I, Athanasou N, et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum. 2006;54:1451-62 pubmed
product information
brand :
R&D Systems
master code :
142-DC
SKU :
142-DC-100
product name :
Recombinant Human DcR3/TNFRSF6B Fc Chimera Protein, CF
description :
The Recombinant Human DcR3/TNFRSF6B Fc Chimera Protein, CF from R&D Systems is derived from Sf 21 (baculovirus). The Recombinant Human DcR3/TNFRSF6B Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.
target :
DcR3/TNFRSF6B
category :
Proteins and Enzymes
unit size :
100 ug
buffer :
Lyophilized from a 0.2 µm filtered solution in MES and NaCl.
conjugate :
Unconjugated
purity :
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
species :
Human
observed molecular weight :
60-65 kDa, reducing conditions
theoretical molecular weight :
57 kDa (monomer)
gene symbol :
TNFRSF6B
details of functionality :
Measured by its ability to inhibit Fas Ligand-induced apoptosis of Jurkat human acute T cell leukemia cells. Cheng, J. et al . (1994) Science 263 :1759. The ED50 for this effect is 0.03-0.15 µg/mL in the presence of 20 ng/mL rhFas Ligand.
endotoxin note :
<0.10 EU per 1 µg of the protein by the LAL method.
catalog number base :
142-DC
accessionNumbers :
O95407
applications :
Bioactivity
source :
Spodoptera frugiperda , Sf 21 (baculovirus)-derived human DcR3/TNFRSF6B protein Human DcR3 (Val 24-His300) Accession # O95407 IEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus
2020 USD :
369
2021 USD :
369 USD
alt names :
DCR3Decoy receptor for Fas ligand, Decoy receptor 3, M68, M68DJ583P15.1.1, TNFRSF6B, TR6, TR6DcR3, tumor necrosis factor receptor superfamily member 6B, tumor necrosis factor receptor superfamily, member 6b, decoy
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.